Several new insulins have come to the market recently; three high strength insulins which have concentrations greater than the previously standard strength of U100 and biosimilar insulin.
The Trustees of IDDT have discussed the introduction of different strengths of insulin in depth and strongly expressed their concerns about the risks of errors by people with diabetes, health professionals and hospitals. These concerns come from their experiences of the introduction of the first genetically modified human insulin in the 1980s when there was a dearth of evidence of benefit and many people with diabetes were not informed of the differences from their previous natural animal insulin.